PURDUE PHARMA, LP for PURDUE PHARMA LP
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
H.R.4710 - Pharmaceutical Independence Long-Term Readiness Reform Act and H.R.6482 - Protecting Our Pharmaceutical Supply Chain from China Act of 2020; monitoring activity regarding potential incentives to increase domestic manufacturing of pharmaceutical products. S. 2543 Prescription Drug Pricing Reduction Act of 2019; monitoring to understand potential new obligations on pharmaceutical manufacturers regarding price transparency and implications for applicable federal programs. H.R. 7574 - The Strengthening America's Strategic National Stockpile Act of 2020; monitoring activity to better understand what modifications may be made to medications required to be included as part of national stockpile. H.R. 3878 - The Block, Report, And Suspend Shipments Act of 2019, H.R. 4812 Ensuring Compliance Against Drug Diversion Act of 2019, and H.R. 4806 DEBAR Act of 2019; monitoring activity on these bills as it relates to potential modifications to DEA registration procedures and reporting.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHLEEN KONKA New | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.